130 related articles for article (PubMed ID: 14680492)
1. Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Evans DG; Howell A
Breast Cancer Res; 2004; 6(1):E7. PubMed ID: 14680492
[TBL] [Abstract][Full Text] [Related]
2. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
3. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
[TBL] [Abstract][Full Text] [Related]
4. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
[TBL] [Abstract][Full Text] [Related]
5. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
Tilanus-Linthorst MM; Alves C; Seynaeve C; Menke-Pluymers MB; Eggermont AM; Brekelmans CT
Br J Surg; 2006 Aug; 93(8):961-8. PubMed ID: 16758466
[TBL] [Abstract][Full Text] [Related]
6. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
7. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
8. Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients.
Tilanus-Linthorst MM; Bartels KC; Alves C; Bakri B; Crepin E; van den Ouweland A; Klijn JG; Meijers-Heijboer H; Brekelmans CT
Breast Cancer Res Treat; 2006 Jan; 95(2):117-23. PubMed ID: 16319990
[TBL] [Abstract][Full Text] [Related]
9. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
Narod SA
Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
[TBL] [Abstract][Full Text] [Related]
11. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
[TBL] [Abstract][Full Text] [Related]
12. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
Ahn SH; Son BH; Yoon KS; Noh DY; Han W; Kim SW; Lee ES; Park HL; Hong YJ; Choi JJ; Moon SY; Kim MJ; Kim KH; Kwak BS; Cho DY
Cancer Lett; 2007 Jan; 245(1-2):90-5. PubMed ID: 16455195
[TBL] [Abstract][Full Text] [Related]
14. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
15. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
16. Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side.
Garber JE; Golshan M
J Clin Oncol; 2009 Dec; 27(35):5862-4. PubMed ID: 19858367
[No Abstract] [Full Text] [Related]
17. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of BRCA-associated breast cancer: a summary of evidence.
Bordeleau L; Panchal S; Goodwin P
Breast Cancer Res Treat; 2010 Jan; 119(1):13-24. PubMed ID: 19789974
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Armstrong K; Weber BL
Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
[No Abstract] [Full Text] [Related]
[Next] [New Search]
